Everolimus for Cancer With TSC1 or TSC2 Mutation
Clinical trial NCT02201212 · COMPLETED
Trial details
- NCT number
- NCT02201212
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-01
- Primary completion
- 2019-06-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.